177 related articles for article (PubMed ID: 34105813)
1. High-risk follicular lymphoma: Treatment options.
Kahl B
Hematol Oncol; 2021 Jun; 39 Suppl 1():94-99. PubMed ID: 34105813
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma.
Ma J; Zhao D; Zhen B; Xia Y; Gong Q; Chen W
J Comp Eff Res; 2023 Dec; 12(12):e230073. PubMed ID: 37916709
[TBL] [Abstract][Full Text] [Related]
3. Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: A systematic review and network meta-analysis of randomized trials.
Chu Y; Liu Y; Yu Z; Zhan L; Lu T; Jiang Y; Fang X; Zhou X; Wang X
Cancer; 2024 Apr; 130(7):1072-1082. PubMed ID: 38041532
[TBL] [Abstract][Full Text] [Related]
4. Advancements in the Management of Follicular Lymphoma: A Comprehensive Review.
Merryman R; Mehtap Ö; LaCasce A
Turk J Haematol; 2024 Apr; ():. PubMed ID: 38660754
[TBL] [Abstract][Full Text] [Related]
5. Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?
Fowler N
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):277-283. PubMed ID: 27913492
[TBL] [Abstract][Full Text] [Related]
6. Novel agents in follicular lymphoma: choosing the best target.
Sehn LH
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):284-292. PubMed ID: 27913493
[TBL] [Abstract][Full Text] [Related]
7. Follicular lymphoma: an update on diagnosis, prognosis, and management.
Mozas P; Sorigué M; López-Guillermo A
Med Clin (Barc); 2021 Nov; 157(9):440-448. PubMed ID: 34210513
[TBL] [Abstract][Full Text] [Related]
8. Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies.
Rodgers TD; Casulo C; Boissard F; Launonen A; Parreira J; Cartron G
Oncol Ther; 2021 Dec; 9(2):329-346. PubMed ID: 34319556
[TBL] [Abstract][Full Text] [Related]
9. Vulnerabilities in the tumor and microenvironment in follicular lymphoma.
Araujo-Ayala F; Pérez-Galán P; Campo E
Hematol Oncol; 2021 Jun; 39 Suppl 1():83-87. PubMed ID: 34105816
[TBL] [Abstract][Full Text] [Related]
10. Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma.
Levi G; Rocchetti C; Magri R; Uccelli S; Bottone D; Quadri F; Novali M; Santin AD; Bezzi M
Monaldi Arch Chest Dis; 2021 Jun; 91(4):. PubMed ID: 34121379
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
[TBL] [Abstract][Full Text] [Related]
12. Reduced bendamustine for elderly patients with follicular lymphoma.
Masamoto Y; Shimura A; Kurokawa M
Ann Hematol; 2022 Mar; 101(3):713-715. PubMed ID: 34152427
[No Abstract] [Full Text] [Related]
13. Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma.
Pongas G; Cheson B
Blood Lymphat Cancer; 2021; 11():55-66. PubMed ID: 34354386
[TBL] [Abstract][Full Text] [Related]
14. Is it time for PET-guided therapy in follicular lymphoma?
Trotman J; Pettitt AR
Blood; 2022 Mar; 139(11):1631-1641. PubMed ID: 34260714
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.
Izutsu K; Ando K; Nishikori M; Shibayama H; Teshima T; Kuroda J; Kato K; Imaizumi Y; Nosaka K; Sakai R; Hojo S; Nakanishi T; Rai S
Cancer Sci; 2021 Sep; 112(9):3627-3635. PubMed ID: 34159682
[TBL] [Abstract][Full Text] [Related]
16. Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches.
Silkenstedt E; Dreyling M
Hematol Oncol; 2021 Jun; 39 Suppl 1():31-38. PubMed ID: 34105823
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
Schuster SJ
Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
[TBL] [Abstract][Full Text] [Related]
18. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
19. Diffuse Large B-Cell Lymphoma.
Lang R; Gill MJ
N Engl J Med; 2021 Jun; 384(23):2261-2262. PubMed ID: 34107188
[No Abstract] [Full Text] [Related]
20. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
Ma S; Seymour JF; Brander DM; Kipps TJ; Choi MY; Anderson MA; Humphrey K; Al Masud A; Pesko J; Nandam R; Salem AH; Chyla B; Arzt J; Jacobson A; Kim SY; Roberts AW
Blood; 2021 Sep; 138(10):836-846. PubMed ID: 34115103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
